...
search icon
snti-img

Senti Biosciences Inc, Common Stock

SNTI

NAQ

$3.2

+$0.15

(4.92%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$82.94M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
8.2432
Volume info-icon
This is the total number of shares traded during the most recent trading day.
24.85K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.32
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.52 L
$10 H
$3.2

About Senti Biosciences Inc, Common Stock

Senti Biosciences, Inc., a clinical stage biotechnology company, develops cell and gene therapies engineered with its gene circuit platform technologies for patients living with incurable diseases. Its lead product candidates utilize off-the-shelf healthy adult donor derived natural killer (NK) cells to create CAR-NK cells outfitted with gene circuit technologies in various oncology indications with unmet need. The company's product candidates also include SENTI-202, a logic gated off-the-shelf CAR-NK cell therapy for the treatment of blood cancers and relapsed/refractory hematological malignancies, including acute myeloid leukemia; and SENTI-301A, an off-the-shelf CAR-NK cell therapy for the treatment of solid tumors and hepatocellular carcinoma. In addition, it develops the tumor-associated antigen and protective antigen paired discovery platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. Further, its pipeline includes preclinical programs, which comprise a solid tumor cell therapy program; and partnered programs related to gene therapies for tissue-directed targets, as well as partnered programs related to cell therapies for regenerative medicines. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSNTISectorS&P500
1-Week Return0.63%-1.91%-1.87%
1-Month Return-27.77%-3.82%8.93%
3-Month Return-16.88%-11.56%-2.39%
6-Month Return46.79%-10.21%-2.41%
1-Year Return-8.83%-9.91%10.88%
3-Year Return-96.78%-0.28%46.93%
5-Year Return-96.79%31.29%94.89%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue394.00K2.29M4.29M2.56M-[{"date":"2020-12-31","value":9.19,"profit":true},{"date":"2021-12-31","value":53.45,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":59.75,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue15.96M3.01M3.92M5.24M-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":18.86,"profit":true},{"date":"2022-12-31","value":24.57,"profit":true},{"date":"2023-12-31","value":32.87,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Gross Profit(15.56M)(719.00K)4.29M(2.68M)-[{"date":"2020-12-31","value":-363.09,"profit":false},{"date":"2021-12-31","value":-16.78,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-62.6,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Gross Margin(3949.75%)(31.38%)100.00%(104.76%)-[{"date":"2020-12-31","value":-3949.75,"profit":false},{"date":"2021-12-31","value":-31.38,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-104.76,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Operating Expenses25.09M42.74M74.92M95.29M61.04M[{"date":"2020-12-31","value":26.33,"profit":true},{"date":"2021-12-31","value":44.85,"profit":true},{"date":"2022-12-31","value":78.62,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":64.06,"profit":true}]
Operating Income(24.69M)(40.45M)(70.63M)(92.73M)(61.04M)[{"date":"2020-12-31","value":-2469400000,"profit":false},{"date":"2021-12-31","value":-4044600000,"profit":false},{"date":"2022-12-31","value":-7062900000,"profit":false},{"date":"2023-12-31","value":-9272700000,"profit":false},{"date":"2024-12-31","value":-6103900000,"profit":false}]
Total Non-Operating Income/Expense4.92M(14.86M)14.12M12.89M9.20M[{"date":"2020-12-31","value":34.84,"profit":true},{"date":"2021-12-31","value":-105.25,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":91.27,"profit":true},{"date":"2024-12-31","value":65.13,"profit":true}]
Pre-Tax Income(19.86M)(55.32M)(58.21M)(83.41M)(52.79M)[{"date":"2020-12-31","value":-1986200000,"profit":false},{"date":"2021-12-31","value":-5531900000,"profit":false},{"date":"2022-12-31","value":-5821000000,"profit":false},{"date":"2023-12-31","value":-8340600000,"profit":false},{"date":"2024-12-31","value":-5279000000,"profit":false}]
Income Taxes150.00K11.00K(12.42M)9.51M-[{"date":"2020-12-31","value":1.58,"profit":true},{"date":"2021-12-31","value":0.12,"profit":true},{"date":"2022-12-31","value":-130.55,"profit":false},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(20.01M)(55.33M)(45.79M)(92.92M)-[{"date":"2020-12-31","value":-2001200000,"profit":false},{"date":"2021-12-31","value":-5533000000,"profit":false},{"date":"2022-12-31","value":-4579100000,"profit":false},{"date":"2023-12-31","value":-9291900000,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(19.86M)(55.32M)(58.21M)(88.25M)(52.79M)[{"date":"2020-12-31","value":-1986200000,"profit":false},{"date":"2021-12-31","value":-5531900000,"profit":false},{"date":"2022-12-31","value":-5821000000,"profit":false},{"date":"2023-12-31","value":-8825100000,"profit":false},{"date":"2024-12-31","value":-5279000000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(19.86M)(55.32M)(45.79M)(92.92M)(52.79M)[{"date":"2020-12-31","value":-1986200000,"profit":false},{"date":"2021-12-31","value":-5531900000,"profit":false},{"date":"2022-12-31","value":-4579100000,"profit":false},{"date":"2023-12-31","value":-9291900000,"profit":false},{"date":"2024-12-31","value":-5279000000,"profit":false}]
EPS (Diluted)-(0.13)(1.41)(1.02)(9.69)[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":-13,"profit":false},{"date":"2022-12-31","value":-140.5,"profit":false},{"date":"2023-12-31","value":-101.91,"profit":false},{"date":"2024-12-31","value":-969.19,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SNTI
Cash Ratio 3.15
Current Ratio 4.22

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SNTI
ROA (LTM) -36.46%
ROE (LTM) -116.64%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SNTI
Debt Ratio Lower is generally better. Negative is bad. 0.54
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.46

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SNTI
Trailing PE 8.24
Forward PE NM
P/S (TTM) 55.46
P/B 2.10
Price/FCF NM
EV/R 134.22
EV/Ebitda NM

FAQs

What is Senti Biosciences Inc share price today?

Senti Biosciences Inc (SNTI) share price today is $3.2

Can Indians buy Senti Biosciences Inc shares?

Yes, Indians can buy shares of Senti Biosciences Inc (SNTI) on Vested. To buy Senti Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SNTI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Senti Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Senti Biosciences Inc (SNTI) via the Vested app. You can start investing in Senti Biosciences Inc (SNTI) with a minimum investment of $1.

How to invest in Senti Biosciences Inc shares from India?

You can invest in shares of Senti Biosciences Inc (SNTI) via Vested in three simple steps:

  • Click on Sign Up or Invest in SNTI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Senti Biosciences Inc shares
What is Senti Biosciences Inc 52-week high and low stock price?

The 52-week high price of Senti Biosciences Inc (SNTI) is $10. The 52-week low price of Senti Biosciences Inc (SNTI) is $1.52.

What is Senti Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Senti Biosciences Inc (SNTI) is 8.2432

What is Senti Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Senti Biosciences Inc (SNTI) is 2.10

What is the Market Cap of Senti Biosciences Inc?

The market capitalization of Senti Biosciences Inc (SNTI) is $82.94M

What is Senti Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Senti Biosciences Inc is SNTI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top